title: Maternal obesity, inflammation, and developmental programming.
abstract: The prevalence of obesity, especially in women of child-bearing age, is a global health concern. In addition to increasing the immediate risk of gestational complications, there is accumulating evidence that maternal obesity also has long-term consequences for the offspring. The concept of developmental programming describes the process in which an environmental stimulus, including altered nutrition, during critical periods of development can program alterations in organogenesis, tissue development, and metabolism, predisposing offspring to obesity and metabolic and cardiovascular disorders in later life. Although the mechanisms underpinning programming of metabolic disorders remain poorly defined, it has become increasingly clear that low-grade inflammation is associated with obesity and its comorbidities. This review will discuss maternal metainflammation as a mediator of programming in insulin sensitive tissues in offspring. Use of nutritional anti-inflammatories in pregnancy including omega 3 fatty acids, resveratrol, curcumin, and taurine may provide beneficial intervention strategies to ameliorate maternal obesity-induced programming.
authors: Liggins Institute and Gravida, National Centre for Growth and Development, University of Auckland, Auckland 1142, New Zealand.
authors: Stephanie A
authors: SA
authors: Segovia
authors: Liggins Institute and Gravida, National Centre for Growth and Development, University of Auckland, Auckland 1142, New Zealand.
authors: Mark H
authors: MH
authors: Vickers
authors: Liggins Institute and Gravida, National Centre for Growth and Development, University of Auckland, Auckland 1142, New Zealand.
authors: Clint
authors: 0000-0002-0659-8694
authors: C
authors: Gray
authors: Liggins Institute and Gravida, National Centre for Growth and Development, University of Auckland, Auckland 1142, New Zealand.
authors: Clare M
authors: CM
authors: Reynolds
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D005260:Female; D047109:Fetal Development; D006801:Humans; D007249:Inflammation; D007333:Insulin Resistance; D009765:Obesity / Q000188:drug therapy / Q000453:epidemiology / Q000378:metabolism / Q000503:physiopathology*; D038081:Organogenesis; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy / Q000453:epidemiology / Q000378:metabolism / Q000503:physiopathology*; D015995:Prevalence
chemical_list: D000893:Anti-Inflammatory Agents